| |
| |
|
| Insider
Information: |
Kunkel Lori Anne |
| Relationship: |
|
| City: |
Sunnyvale |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
93,823 |
|
|
Indirect Shares
|
31,172 |
|
|
| Direct
Value |
$8,436 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
124,995 |
|
|
| Total
Value |
$8,436 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Pharmacyclics Inc |
PCYC |
Chief Medical Officer |
2013-04-30 |
2,842 |
|
0 |
Premium* |
|
|
Loxo Oncology, Inc. |
LOXO |
Director |
2018-10-01 |
0 |
|
0 |
Premium* |
|
|
Curis Inc |
CRIS |
Director |
2019-01-23 |
22,200 |
2018-01-22 |
0 |
Premium* |
|
|
Nurix Therapeutics, Inc. |
NRIX |
Director |
2020-07-23 |
54,027 |
|
0 |
Premium* |
|
|
Enliven Therapeutics Ord Shs |
ELVN |
|
2024-04-08 |
14,754 |
2024-04-08 |
31,172 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
17 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-04-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
31,172 |
|
- |
|
| ELVN |
Enliven Therapeutics Ord ... |
|
– • – |
2024-04-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,754 |
|
- |
|
| NRIX |
Nurix Therapeutics, Inc. |
Director |
– • – |
2020-07-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
54,027 |
|
- |
|
| CRIS |
Curis Inc |
Director |
– • – |
2019-01-23 |
4 |
AS |
$1.05 |
$15,581 |
D/D |
(14,800) |
22,200 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2018-10-01 |
4 |
AS |
$170.20 |
$851,829 |
D/D |
(5,000) |
0 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2018-10-01 |
4 |
OE |
$3.65 |
$18,240 |
D/D |
5,000 |
5,000 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2018-06-15 |
4 |
AS |
$175.64 |
$1,209,689 |
D/D |
(6,840) |
0 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2018-06-14 |
4 |
AS |
$180.28 |
$5,845,564 |
D/D |
(32,392) |
6,840 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2018-06-14 |
4 |
OE |
$3.65 |
$211,708 |
D/D |
32,392 |
39,232 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2018-04-20 |
4 |
AS |
$131.98 |
$663,378 |
D/D |
(5,000) |
6,840 |
0 |
- |
|
| CRIS |
Curis Inc |
Director |
– • – |
2018-01-22 |
4 |
A |
$0.00 |
$0 |
D/D |
185,000 |
185,000 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2017-11-02 |
4 |
AS |
$84.15 |
$424,570 |
D/D |
(5,000) |
11,840 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2017-08-22 |
4 |
AS |
$75.17 |
$751,731 |
D/D |
(10,000) |
16,840 |
0 |
- |
|
| LOXO |
Loxo Oncology, Inc. |
Director |
– • – |
2014-10-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
26,840 |
|
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Medical Officer |
• – – |
2013-04-30 |
4 |
A |
$23.07 |
$21,247 |
D/D |
921 |
2,842 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Medical Officer |
• – – |
2012-10-31 |
4 |
A |
$23.07 |
$21,247 |
D/D |
921 |
1,921 |
0 |
- |
|
| PCYC |
Pharmacyclics Inc |
Chief Medical OfficerOfficer |
• – – |
2011-12-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,000 |
|
- |
|
17 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
